Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942877 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
A Phase 2 study of Sarcoma, Alveolar Soft Part, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT00942877: Completed Phase 2 study of Sarcoma, Alveolar Soft Part, sponsored by National Cancer Institute (NCI).
NCT00942877 is a Phase 2 study of Sarcoma, Alveolar Soft Part that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00942877, a Phase 2 study of Sarcoma, Alveolar Soft Part, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective systemic treatment for patients with alveolar soft part sarcoma. * The drug AZD2171 (cediranib) is an experimental drug, not yet approved by the Food and Drug Administration. The drug blocks the creation of new blood vessels. The drug has had initial clinical trials, and researchers are interested in determining whether cediranib is effective in inhibiting tumor growth in individuals who have alveolar soft part sarcoma. Objectives: \- To find out whether AZD2171 works in patients who have alveolar soft part sarcoma. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with alveolar soft part sarcoma. Design: * After an initial screening visit, patients will take AZD2171 by mouth once a day, every day for the duration of the study. The treatment will be given in 28-day cycles. * Patients will keep a study diary to record the doses taken, any missed doses, and any side effects. * Patients will have the following tests and procedures during the treatment period: clinic visit with physical examination every 2 weeks during cycles 1 and 2, then at the start of each subsequent cycle, regular blood pressure monitoring, blood and urine tests, heart function tests, imagining scans to evaluate tumor size and response to the treatment, and possible tumor biopsy.
Primary Outcome
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)v1.0. A minimal response is defined as a 5% overall response rate (Partial Response (PR) + Complete Response (CR)
Conditions Studied
Interventions
- DRUG AZD2171
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-07-18 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
What the finished NCT00942877 record still lists
NCT00942877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Sarcoma, Alveolar Soft Part appearing as the primary indexed condition, and to 1 intervention - of which AZD2171 is the first listed.
NCT00942877 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00942877 about?
NCT00942877 is a clinical study titled "Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma". Background: * Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective systemic treatment for patients with alveolar soft par...
What is the current status of trial NCT00942877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2009-07-18. Estimated completion is 2024-12-31.
What conditions does trial NCT00942877 study?
This clinical trial studies the following conditions: Sarcoma, Alveolar Soft Part.
What interventions are being tested in trial NCT00942877?
The interventions under investigation include: AZD2171 (DRUG).
Who is sponsoring clinical trial NCT00942877?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00942877 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00942877's enrollment target sits among peer trials
53 1171st of 2000 higher than 820 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI